Dr. Bernard Hamelin, MD, MSc, MBA, is the Global Head of Medical Evidence Generation within the Medical Function at Sanofi, a global healthcare leader that discovers, develops and distributes therapeutic solutions for patients. In that role, he is responsible for delivering evidence required to demonstrate the value of Sanofi products, from early to late phase development. He also helps driving innovative and collaborative activities in order to engage with the changing healthcare landscape and to improve patient outcomes.

Dr. Hamelin is a Medical Doctor trained in Liver diseases and Gastroenterology in Paris from 1984 to 1991. Bernard joined AstraZeneca in 1991 as responsible for GI clinical and medical affairs programs in the French Affiliate. From 1994 to 2001 Bernard occupied different clinical research roles based in Sweden (Goteborg) and in the USA (Philadelphia). He was the lead physician on the esomeprazole (Proton Pump Inhibitor) project and led the emerging GI global product team. In 2001, Bernard was appointed head of the French AstraZeneca affiliate Medical Affairs team, based in Rueil-Malmaison. His team supported the successful launch of different products (incl. Crestor (statin), Symbicort (inhaled glucocorticosteroid), Arimidex (aromatase inhibitor).

Authored by Bernard Hamelin, MD, MSc, MBA